Previous 10 | Next 10 |
RESEARCH TRIANGLE PARK, N.C., April 27, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the European Medicines Agency (EMA) has granted access to the Priority Medicines (PRIME) scheme for BCX9250, a novel, oral activin receptor-like kinase-2 (...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips BioNTech ( BNTX ) rose to fame with the tech that delivered the Pfizer ( PFE ) vaccine, but there’s more there than just the vaccine. BioCryst Pharmaceuticals ( BCRX ) is a commercial-stage biote...
RESEARCH TRIANGLE PARK, N.C., April 21, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2022 financial results Thursday, May 5, 2022. BioCryst management will host a conference call and webcast a...
After announcing a pause in clinical trial enrollment for its biggest pipeline program on April 8, BioCryst Pharmaceuticals (NASDAQ: BCRX) saw its shares take a nosedive that has left them down by more than 21% compared to a mere month ago. Though the rare disease biotech's base of ...
Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) took it on the chin Monday, suffering a nearly 7% decline in value. Not for the first time in recent days, the company was socked by an analyst's increasingly dim view of its prospects. Barclays prognosticator Gena Wang didn'...
BioCryst Pharmaceuticals (NASDAQ:BCRX) is trading lower in the premarket Monday after Barclays downgraded its shares to Equal Weight from Overweight, citing the decision by the commercial-stage biotech to pause enrollment in clinical trials for BCX9930, an oral factor D inhibitor. The setback...
Shares of BioChryst Pharmaceuticals (NASDAQ: BCRX) jumped 14.7% this week, according to data from S&P Global Market Intelligence . The stock opened Monday at $10.40 a share and climbed to its weekly high at $12.76 on Wednesday. The stock has a 52-week low of $10.13 and a 52-...
Piper Sandler is reiterating its overweight rating for BioCryst (NASDAQ:BCRX) arguing that weakness following Friday's announcement of a trial enrollment pause for BCX9930 provides a buying opportunity. The firm has a $24 price target (~121% upside based on Monday's close). Analyst Chris...
BofA Securities has downgraded BioCryst Pharmaceuticals (NASDAQ:BCRX) to neutral from buy citing the company's decision on Friday to pause enrollment in clinical studies involving BCX9930 for paroxysmal nocturnal hemoglobinuria due to elevated serum creatinine levels. The company also lowered...
RESEARCH TRIANGLE PARK, N.C., April 11, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 21 st Annual Needham Virtual Healthcare Conference on Thursday, April 14, 2022, at 11:45 a.m. ET. Links to a...
News, Short Squeeze, Breakout and More Instantly...
BioCryst Pharmaceuticals Inc. Company Name:
BCRX Stock Symbol:
NASDAQ Market:
BioCryst Pharmaceuticals Inc. Website:
RESEARCH TRIANGLE PARK, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the General Directorate of Medicines, Supplies and Drugs (DIGEMID) in Peru has granted approval for oral, once-daily ORLADEYO ® (berotralstat) for t...
2024-06-27 04:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-07 10:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...